These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 17391147

  • 21. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M, Marchionni N, Mannucci E.
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [Abstract] [Full Text] [Related]

  • 22. Insulin detemir: A historical perspective on a modern basal insulin analogue.
    Meneghini L, Liebl A, Abrahamson MJ.
    Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S31-42. PubMed ID: 20394890
    [Abstract] [Full Text] [Related]

  • 23. [Insulin detemir (Levemir)].
    Scheen AJ, Radermecker RP, Philips JC, Paquot N.
    Rev Med Liege; 2005 Oct; 60(10):814-9. PubMed ID: 16358671
    [Abstract] [Full Text] [Related]

  • 24. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.
    Raslová K, Tamer SC, Clauson P, Karl D.
    Clin Drug Investig; 2007 Oct; 27(4):279-85. PubMed ID: 17358100
    [Abstract] [Full Text] [Related]

  • 25. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A, Plank J, Bodenlenz M, Magnes C, Regittnig W, Sinner F, Rønn B, Zdravkovic M, Pieber TR.
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [Abstract] [Full Text] [Related]

  • 26. Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.
    Tripathi S, Chandalia HB, Rao PV, Badgandi M, Patni R, Subbanna PK, Shetty R, Kumar H.
    J Indian Med Assoc; 2011 Apr; 109(4):275-8. PubMed ID: 22187803
    [Abstract] [Full Text] [Related]

  • 27. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM, Perry CM.
    Drugs; 2004 Apr; 64(22):2577-95. PubMed ID: 15516157
    [Abstract] [Full Text] [Related]

  • 28. Innovative insulins--where do analogues fit?
    Phillips LK, Phillips PJ.
    Aust Fam Physician; 2006 Dec; 35(12):969-73. PubMed ID: 17149471
    [Abstract] [Full Text] [Related]

  • 29. Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?
    Russell-Jones D, Danne T, Hermansen K, Niswender K, Robertson K, Thalange N, Vasselli JR, Yildiz B, Häring HU.
    Diabetes Obes Metab; 2015 Oct; 17(10):919-27. PubMed ID: 25974283
    [Abstract] [Full Text] [Related]

  • 30. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
    Chapman TM, Perry CM.
    BioDrugs; 2005 Oct; 19(1):67-9. PubMed ID: 15691219
    [Abstract] [Full Text] [Related]

  • 31. Patient perceptions of insulin detemir as reported through patient telephone surveys.
    Kerney DL, Paradis D, Brunton S.
    Curr Med Res Opin; 2007 Sep; 23(9):2043-9. PubMed ID: 17640448
    [Abstract] [Full Text] [Related]

  • 32. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
    Yenigun M, Honka M.
    Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627
    [Abstract] [Full Text] [Related]

  • 33. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW.
    Clin Ther; 2007 Mar; 29 Suppl D():S135-44. PubMed ID: 18191065
    [Abstract] [Full Text] [Related]

  • 34. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
    Dailey G, Strange P.
    Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
    [Abstract] [Full Text] [Related]

  • 35. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.
    Frier BM, Russell-Jones D, Heise T.
    Diabetes Obes Metab; 2013 Nov; 15(11):978-86. PubMed ID: 23551900
    [Abstract] [Full Text] [Related]

  • 36. Is a failure to recognize an increase in food intake a key to understanding insulin-induced weight gain?
    Ryan M, Livingstone MB, Ducluzeau PH, Sallé A, Genaitay M, Ritz P.
    Diabetes Care; 2008 Mar; 31(3):448-50. PubMed ID: 18086874
    [Abstract] [Full Text] [Related]

  • 37. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul 03; 48(1238):54-5. PubMed ID: 16841022
    [Abstract] [Full Text] [Related]

  • 38. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A.
    Clin Ther; 2007 Jun 03; 29(6):987-99. PubMed ID: 17692716
    [Abstract] [Full Text] [Related]

  • 39. Diabetes and weight management.
    Lau DC.
    Prim Care Diabetes; 2010 Apr 03; 4 Suppl 1():S24-30. PubMed ID: 20394888
    [Abstract] [Full Text] [Related]

  • 40. Insulin treatment and the problem of weight gain in type 2 diabetes.
    Carver C.
    Diabetes Educ; 2006 Apr 03; 32(6):910-7. PubMed ID: 17102158
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.